Heart imaging with a new radiotracer
This study tests a new imaging agent, 18F-TPP, that may help doctors see how well the heart's cells are working. It involves two PET scans and an MRI, and is for healthy volunteers to establish normal readings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be in good general health, as confirmed by a physical exam, blood and urine tests, and an ECG.
- If you are a woman who could become pregnant, you must agree to use an acceptable form of birth control during the study.
- You cannot have any known heart disease, heart attack history, or abnormal ECG at screening.
- You must not have any metal implants or other conditions that would make an MRI unsafe (like a pacemaker, claustrophobia, or certain metal fragments).
- You must not have participated in other radiation-related research or have excessive workplace radiation exposure within the past year.
- If you have an arterial line (a small tube placed in an artery), you cannot have a bleeding disorder, take blood thinners, or use aspirin or NSAIDs for the required time before the scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new radioactive dye called [18F]GATT-44 to see how well it can show a specific brain protein on a PET scan. It may help researchers better understand brain conditions in the future.
This study tests a new imaging agent that highlights inflammation in the heart after a heart attack. It may help doctors see how much damage occurred and guide treatment.
This study tests a new imaging agent that helps doctors see amyloid buildup in the heart using a PET scan. It may help diagnose cardiac amyloidosis more accurately and guide treatment decisions.
This study compares two types of radioactive tracers used during heart PET scans to see if one is better at detecting blocked arteries. Participation involves receiving one of the tracers during your routine scan and may help improve heart disease diagnosis.
This trial is testing a new imaging method (68Ga-FAPI PET/CMR) to better see and understand heart problems. It might help doctors diagnose or monitor conditions like heart failure or inflammation.
This study uses two imaging scans to see if parts of your heart muscle are still alive but not working well. This could help doctors decide if you might benefit from heart bypass surgery.
Hear when a new Membrane Potential Mapping trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.